Potential Clinical Applications of the CXCR4 Antagonist Bicyclam AMD3100
The DOI matches its Crossref record.
Abstract
The bicyclam AMD3100 (originally called JM3100), in which the two cyclam rings are tethered by an aromatic bridge, emanated from JM2763, where the two cyclam moieties are tethered by an aliphatic linker - JM2763 in turn originated from JM1657, where the cyclam rings are directly linked to one another via a C-C bridge, and which was identified as an impurity, showing anti-HIV activity, in a commercial cyclam preparation. AMD3100 proved very effective against HIV-1 and HIV-2, inhibiting virus replication within the nM range, without toxicity for the host cells at concentrations that were > 100,000-fold higher than those required to inhibit HIV replication. The anti-HIV activity of AMD3100 appeared to be confined to the T-lymphotropic (X4) HIV strains, i.e. those strains that use the CXCR4 receptor to enter their target cells, and AMD3100 as of today still stands as one of the most potent and selective CXCR4 antagonists ever discovered. Hence, AMD3100 was found to interfere with a number of (patho)physiological processes which depend on the interaction of CXCR4 with its natural ligand, stromal derived factor (SDF-1) and which play an important role in rheumatoid, allergic and malignant diseases. AMD3100 has been shown to mobilize CD34+ stem cells from the bone marrow into the bloodstream and has also been shown to augment migration of bone marrow-derived endothelial progenitor cells into sites of neovascularization after myocardial infarction. Currently, AMD3100 is actively pursued as a stem cell mobilizer for transplantation in patients with multiple myeloma and non-Hodgkin's lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
The SDF-1–CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis
Petit, I., Jin, D., & Rafii, S. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.05.007 · Cited by 603
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma
Alsayed, Y., Ngo, H., Runnels, J., Leleu, X., Singha, U. K., Pitsillides, C. M., Spencer, J. A., Kimlinger, T., Ghobrial, J. M., Jia, X., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035857 · Cited by 478
Mimeault, M., Hauke, R., & Batra, S. K. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100301 · Cited by 450
Bowie, M. B., McKnight, K. D., Kent, D. G., McCaffrey, L., Hoodless, P. A., & Eaves, C. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28310 · Cited by 380
“However, the mobilization of primitive hematopoietic cells can also be stimulated by blocking CXCL12/CXCR4 signaling, as achieved by in vivo administration of AMD3100, a CXCL12 antagonist (40).”
Background
Metadata
- Authors
- De Clercq, E.
- Venue
- Mini-Reviews in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-09-01
- Volume
- 5
- Issue
- 9
- Pages
- 805-824
- ISSN
- 1389-5575 (ISSN-L)
- OpenAlex
- W2062741733
- Cited by
- 86
- References
- 0
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential Clinical Applications of the CXCR4 Antagonist Bicyclam AMD3100. https://app.cochat.ai/papers/10.2174/1389557054867075
- The paper
- De Clercq, E. (2005). Potential Clinical Applications of the CXCR4 Antagonist Bicyclam AMD3100. Mini-Reviews in Medicinal Chemistry. https://doi.org/10.2174/1389557054867075
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.